A RANDOMIZED PHASE 2 STUDY OF CASDOZOKITUG IN COMBINATION WITH
TORIPALIMAB PLUS BEVACIZUMAB IN PARTICIPANTS WITH UNRESECTABLE
AND/OR LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA
- Registry ID
- CHS-388-202
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- COHERUS BIOSCIENCES INC.
- Start date
- 2026-07-31
- Last update
- 2025-03-21
Conditions
- ADVANCED HEPATOCELLULAR CARCINOMA
Related clinical trials
- A PHASE III, RANDOMISED, OPEN-LABEL, SPONSOR-BLINDED, MULTICENTRE STUDY OF
RILVEGOSTOMIG IN COMBINATION WITH BEVACIZUMAB WITH OR WITHOUT TREMELIMUMAB AS
FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA
(ARTEMIDE-HCC01)
- A MULTICENTER, OPEN-LABEL, FIRST-IN-HUMAN STUDY OF TYRA-430 IN ADVANCED
HEPATOCELLULAR CARCINOMA AND OTHER SOLID TUMORS WITH ACTIVATING FGF/FGFR
PATHWAY ABERRATIONS (SURF431)
- A PHASE 1/2, SAFETY CONFIRMATION AND DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF RELATLIMAB IN COMBINATION WITH NIVOLUMAB AND BEVACIZUMAB IN TREATMENT-NAIVE ADVANCED/METASTATIC HEPATOCELLULAR CARCINOMA (RELATIVITY-106)
- A RANDOMIZED, CONTROLLED PHASE 3 STUDY OF CABOZANTINIB (XL184) IN COMBINATION WITH ATEZOLIZUMAB VERSUS SORAFENIB IN SUBJECTS WITH ADVANCED HEPATOCELLULAR CARCINOMA WHO HAVE NOT RECEIVED PREVIOUS SYSTEMIC ANTICANCER THERAPY
- PEMBROLIZUMAB AND STEREOTACTIC RADIOTHERAPY COMBINED IN SUBJECTS WITH ADVANCED HEPATOCELLULAR CARCINOMA - A PHASE II STUDY (PEMRAD)
- A PHASE III STUDY OF PEMBROLIZUMAB (MK-3475) VS. BEST SUPPORTIVE CARE AS SECOND-LINE THERAPY IN SUBJECTS WITH PREVIOUSLY SYSTEMICALLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA (KEYNOTE-240)
View on source registry